Structured, confidential coordination for international families seeking access to Switzerland's leading neuroscience institutions — neurosurgery, neurorehabilitation, and comprehensive neurological care
If your family is facing a serious neurological diagnosis, you are likely making decisions under uncertainty while daily life is already under strain. You may be trying to understand complex imaging, rapidly changing symptoms, and conflicting recommendations at the same time. In this situation, families usually need a pathway that is calm, precise, and tightly coordinated: clear records, controlled communication, and reliable institutional sequencing from first review to rehabilitation planning.
For strategic context, review the confidential healthcare coordination Switzerland pillar to understand governance, confidentiality standards, and non-clinical coordination boundaries across specialties.
SwissAtlas is not a medical institution. We do not provide medical advice, diagnosis, or treatment recommendations. Our role is to facilitate structured, confidential coordination between international families and trusted Swiss neuroscience institutions, ensuring that administrative and logistical aspects are handled with absolute discretion.
Switzerland's neuroscience institutions combine advanced neuroimaging capabilities, microsurgical and stereotactic expertise, comprehensive neurorehabilitation programmes, and cutting-edge research within a regulatory framework that prioritises quality, safety, and patient privacy.
SwissAtlas operates as a structured institutional coordination platform, not a medical directory or information service. Our role is to facilitate confidential, curated introductions between international families and trusted Swiss medical institutions that have demonstrated institutional excellence, regulatory compliance, and a commitment to the highest standards of patient care.
SwissAtlas does not provide medical advice, diagnostic assessments, or treatment recommendations. We do not evaluate, rank, or endorse specific medical institutions, physicians, or clinical programmes. Our coordination function is strictly non-clinical and administrative, encompassing the structuring and secure transmission of medical documentation, the identification of relevant institutional options based on the family's stated requirements, and the management of logistical and administrative dimensions of the patient journey.
The relationship between the patient and the treating medical institution remains direct and independent. SwissAtlas serves as an intermediary layer that handles administrative coordination, documentation management, appointment scheduling, accommodation planning, transport logistics, and communication facilitation — all while maintaining the highest standards of discretion and confidentiality consistent with Swiss data protection legislation.
Swiss institutions operate under rigorous regulatory oversight at both federal and cantonal levels, ensuring institutional quality, clinical governance, and patient safety. The Swiss Federal Act on Data Protection provides among the strongest privacy protection frameworks globally, creating an environment where sensitive medical information is handled with the utmost care and legal protection.
For international families considering neurology coordination in Switzerland, SwissAtlas provides a structured pathway that reduces administrative complexity, ensures proper documentation handling, and facilitates efficient engagement with appropriate institutional partners. This coordination model is designed for families who value discretion, structured processes, and institutional-level service delivery.
SwissAtlas's neurology coordination services are designed for international families and individuals who require structured, confidential access to Swiss medical institutions. The following profiles typically engage with our coordination platform:
This coordination service is not designed for routine medical consultations or standard healthcare needs that can be addressed through conventional channels. SwissAtlas focuses on cases that require structured institutional coordination, administrative precision, and the level of discretion and service delivery that characterises Switzerland's private healthcare coordination model.
Neurological disorders are the leading cause of disability-adjusted life years (DALYs) globally. The Lancet Neurology Commission on the Global Burden of Neurological Disorders reported that in 2021, neurological conditions affected over 3.4 billion people — nearly 43% of the world's population. Stroke is the second leading cause of death and the third leading cause of combined death and disability globally. Dementia affects over 55 million people worldwide, with projections reaching 139 million by 2050.
The WHO Brain Health initiative highlights the enormous global burden of neurological conditions and significant disparities in access to neurological care. Epilepsy affects approximately 50 million people globally. Parkinson's disease prevalence has more than doubled in the past 25 years, affecting over 8.5 million people. Multiple sclerosis affects approximately 2.8 million people worldwide. Brain tumours — both primary and metastatic — represent a significant cause of neurological morbidity and mortality across all age groups.
These epidemiological realities, combined with the complexity of neurological diagnosis and the specialisation required for advanced neurological treatment, contribute to international patients seeking access to centres of neurological excellence.
Brain tumour management requires close collaboration between neurosurgeons, neuro-oncologists, radiation oncologists, and neuropathologists. The 2021 WHO Classification integrated molecular markers — including IDH mutation status, 1p/19q codeletion, MGMT promoter methylation, and histone mutations — fundamentally changing diagnostic and prognostic assessment. Surgical resection using microsurgical techniques, intraoperative MRI, fluorescence-guided surgery (5-ALA), awake craniotomy for tumours in eloquent brain areas, and computer-assisted neuronavigation aims to maximise tumour removal while preserving neurological function.
Stereotactic radiosurgery (Gamma Knife, CyberKnife) delivers highly focused radiation to brain tumours and vascular malformations without open surgery. This approach is particularly valuable for small to medium-sized tumours, brain metastases, acoustic neuromas, meningiomas, and residual or recurrent tumours after previous surgery. Proton therapy offers additional precision for tumours near critical structures. Systemic treatment options for malignant brain tumours include temozolomide chemotherapy, bevacizumab, tumour treating fields (TTFields), and clinical trials evaluating targeted therapies and immunotherapy approaches.
Stroke management has been transformed by advances in acute treatment — including intravenous thrombolysis and endovascular mechanical thrombectomy — and by the establishment of comprehensive stroke centres with 24/7 interventional capabilities. Swiss stroke centres adhere to European Stroke Organisation guidelines and participate in international quality registries. For haemorrhagic stroke and intracranial aneurysms, both microsurgical clipping and endovascular coiling/flow diversion are available, with the treatment approach determined by aneurysm characteristics and patient factors.
Arteriovenous malformations (AVMs) — complex vascular anomalies with risk of haemorrhage — may be managed with microsurgical resection, stereotactic radiosurgery, endovascular embolisation, or multimodal combinations depending on the Spetzler-Martin grade and location. Cavernous malformations (cavernomas) causing symptomatic haemorrhage or seizures may require microsurgical excision. Moyamoya disease — a progressive cerebrovascular condition — is managed with revascularisation surgery (STA-MCA bypass) at specialised centres.
Approximately 30% of epilepsy patients do not achieve adequate seizure control with medication alone (drug-resistant epilepsy). For these patients, epilepsy surgery can be transformative — temporal lobe epilepsy surgery achieves seizure freedom in 60–80% of carefully selected patients. The presurgical evaluation pathway is rigorous and includes prolonged video-EEG monitoring, high-resolution MRI with epilepsy-specific protocols, PET imaging, neuropsychological testing, and where indicated, invasive monitoring with stereo-EEG electrodes to precisely localise the seizure onset zone.
Surgical options include temporal lobectomy, lesionectomy, cortical resection, hemispherotomy, corpus callosotomy, and responsive neurostimulation (RNS). Stereotactic laser ablation (LITT) offers a minimally invasive alternative for selected patients. Vagus nerve stimulation (VNS) provides adjunctive therapy for patients who are not surgical candidates.
Movement disorders encompass a range of neurological conditions characterised by abnormal voluntary or involuntary movements. Parkinson's disease management involves a combination of pharmacological therapy (levodopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors), physiotherapy, speech therapy, and in advanced stages, device-aided therapies including deep brain stimulation (DBS) and continuous infusion therapies (levodopa-carbidopa intestinal gel, subcutaneous apomorphine).
Deep brain stimulation — targeting the subthalamic nucleus (STN) or globus pallidus internus (GPi) for Parkinson's disease, the ventral intermediate nucleus (VIM) for essential tremor, and the GPi for dystonia — has been established as an effective treatment for appropriately selected patients. MRI-guided focused ultrasound (MRgFUS) represents a newer, non-invasive alternative for tremor treatment that creates a precise thalamotomy without surgical incision.
Multiple sclerosis (MS) treatment has been revolutionised by the development of disease-modifying therapies (DMTs) that reduce relapse rates and delay disability progression. The therapeutic landscape now includes injectable therapies (interferon-beta, glatiramer acetate), oral therapies (fingolimod, siponimod, dimethyl fumarate, teriflunomide, cladribine), and highly effective monoclonal antibodies (natalizumab, ocrelizumab, ofatumumab, alemtuzumab). Autologous haematopoietic stem cell transplantation (aHSCT) is available at selected Swiss centres for aggressive MS refractory to conventional DMTs.
Swiss neuroscience centres provide comprehensive evaluation and management of neuromuscular conditions including amyotrophic lateral sclerosis (ALS), myasthenia gravis, muscular dystrophies, inflammatory myopathies, Charcot-Marie-Tooth disease, and peripheral neuropathies. Advanced electrodiagnostic testing (EMG/NCS), neuromuscular ultrasound, muscle biopsy with comprehensive histopathological and genetic analysis, and access to emerging gene therapies characterise the Swiss approach.
Swiss neurological institutions employ the most advanced diagnostic platforms available. 3-Tesla MRI with structural, functional (fMRI), diffusion tensor imaging (DTI/tractography), perfusion, and spectroscopy capabilities provides comprehensive brain assessment. 7-Tesla MRI — available at selected Swiss research centres — offers unprecedented spatial resolution for epilepsy evaluation, small vessel disease assessment, and neurodegenerative disease research. PET-CT with specialised neurological tracers (FDG, amyloid, tau, DOPA) enables molecular-level assessment of brain function and pathology.
Neurophysiological diagnostics — including routine and prolonged video-EEG, high-density EEG, magnetoencephalography (MEG), evoked potentials, and comprehensive nerve conduction and electromyography studies — provide functional assessment of the nervous system. Genetic testing panels and whole-exome/genome sequencing are available for hereditary neurological conditions. Cerebrospinal fluid analysis with advanced biomarker assessment (neurofilament light chain, oligoclonal bands, specific antibodies) supports diagnostic precision.
Advanced neuroscience infrastructure including 7-Tesla MRI, Gamma Knife/CyberKnife, DBS, and comprehensive neurorehabilitation. Strong privacy protections. Personalised care. World-class rehabilitation in therapeutic settings. Costs 30–50% below US equivalents. Multilingual teams.
Largest neuroscience research centres globally. Broadest clinical trial access. Highest procedural volumes for complex neurosurgery. Significantly higher costs. Variable rehabilitation integration. Leading DBS and epilepsy surgery programmes.
Strong tradition in neurosurgery and neurology. Established epilepsy surgery centres. Competitive costs below Swiss levels. High volumes for DBS and brain tumour surgery. Good rehabilitation infrastructure.
Growing neuroscience capabilities. Significantly lower costs. Modern facilities at selected centres. Important to verify subspecialist expertise for complex neurological conditions.
Neurological treatment costs vary significantly based on the condition, diagnostic requirements, treatment modality, and rehabilitation needs. Swiss institutions provide transparent pre-treatment estimates. SwissAtlas provides general cost guidance; specific estimates come from the treating institution.
International healthcare mobility represents a significant and growing dimension of the global health landscape. The OECD has documented increasing cross-border patient movement driven by factors including access to specialised expertise, waiting time differentials, regulatory framework considerations, and the pursuit of clinical environments aligned with individual patient expectations regarding quality, privacy, and care coordination. The World Health Organization recognises that patient mobility raises important considerations related to continuity of care, quality assurance, data protection, and ethical standards — all of which must be addressed within structured institutional frameworks.
Switzerland occupies a distinctive position within this landscape. The Swiss healthcare system consistently ranks among the highest-performing globally according to multiple indices, characterised by universal access, high per-capita healthcare expenditure, strong regulatory oversight, and a decentralised institutional model that fosters both competition and quality. For international patients seeking neurological care, Switzerland's institutional positioning reflects several structural advantages: regulatory predictability under federal and cantonal legislation, strong institutional governance frameworks, comprehensive data protection under the Federal Act on Data Protection (FADP), and a long-established tradition of receiving international patients within a culture of discretion and institutional integrity.
The coordination of international patient pathways within this institutional context requires structured administrative facilitation that bridges the gap between the patient's home healthcare environment and the Swiss institutional framework. This coordination function — distinct from any clinical or advisory role — ensures that administrative, logistical, and communicative dimensions of the patient journey are managed with the same level of professionalism and precision that characterises Swiss institutional healthcare delivery. [Internal link: Why Switzerland Private Healthcare]
The international patient coordination pathway for neurological care in Switzerland follows a structured sequence designed to ensure administrative clarity, institutional alignment, and logistical precision at every stage. This pathway operates independently of all clinical decision-making, which remains exclusively within the domain of the patient and their treating medical professionals.
The coordination process begins with a confidential enquiry, during which the patient or their representative provides a general description of the medical situation and coordination requirements. All communications are handled under strict confidentiality protocols consistent with Swiss data protection legislation. No medical assessment or clinical opinion is provided at this stage or at any subsequent stage of the coordination process.
Existing medical documentation — including diagnostic imaging, laboratory results, pathology reports, operative notes, and clinical correspondence — is organised into a structured format suitable for institutional review. This administrative function ensures that the relevant Swiss institution receives a complete, organised, and properly formatted file, facilitating efficient preliminary assessment by the institution's clinical team.
Based on the general nature of the clinical situation and the patient's expressed requirements — including language preferences, privacy considerations, geographical preferences within Switzerland, and logistical factors — appropriate Swiss institutions with relevant neuroscience capabilities are identified. This process is informational and facilitative only; no clinical recommendation or institutional ranking is provided. The patient retains complete autonomy in institutional selection. [Internal link: Private Coordination Services]
Once the patient has selected an institution and the clinical team has confirmed the proposed evaluation or treatment pathway, comprehensive pre-arrival logistics are coordinated. This includes appointment scheduling, accommodation arrangements near the treating institution, transport logistics, visa documentation support where required, interpreter arrangements, and cultural accommodation planning — including dietary requirements and any specific needs.
During the active treatment phase, coordination services ensure that administrative and logistical dimensions continue to function seamlessly. This includes communication facilitation between the patient's family and institutional administrative contacts, schedule coordination for multiple appointments or procedures, accommodation management, and practical support for accompanying family members. All clinical matters remain under the exclusive direction of the treating medical team.
For cases requiring post-treatment rehabilitation — which is particularly relevant in neurological care — coordination services extend to the identification and arrangement of appropriate rehabilitation facilities, transfer logistics, communication continuity between the treating institution and the rehabilitation team, and ongoing family support. Switzerland's extensive rehabilitation infrastructure provides a range of options suited to different clinical requirements and personal preferences.
The final phase of coordination addresses the patient's transition back to their home healthcare environment. This includes facilitation of comprehensive medical summary transmission to the patient's home-country physicians, coordination of follow-up schedules, arrangement of any required medical equipment or medication for the return journey, and establishment of communication channels for ongoing institutional follow-up as directed by the treating medical team. [Internal link: International Patient Process]
The handling of medical data in the context of international patient coordination requires the highest standards of security, confidentiality, and regulatory compliance. Switzerland's legal framework for data protection — governed by the Federal Act on Data Protection (FADP, revised 2023) and supplemented by cantonal health legislation — provides one of the most comprehensive privacy protection regimes globally. The FADP imposes strict requirements on the processing, storage, transmission, and retention of personal data, including heightened protections for health-related information classified as sensitive personal data.
Within this legal framework, all medical documentation transmitted as part of the coordination process is handled using secure, encrypted communication channels. Access to patient files is restricted to authorised personnel on a strict need-to-know basis. No medical data is retained beyond the period required for the specific coordination mandate, and data deletion protocols are applied in accordance with the patient's instructions and applicable legal requirements.
Swiss medical professional secrecy — a legal obligation enforceable under the Swiss Criminal Code (Article 321) — provides an additional layer of protection that applies to all healthcare professionals involved in the patient's care. Breach of medical professional secrecy is a criminal offence in Switzerland, providing a level of legal deterrence that reinforces institutional confidentiality commitments.
For international patients from jurisdictions with differing data protection standards, Switzerland's independent data protection framework — recognised by the European Commission as providing an adequate level of protection — offers significant assurance regarding the handling of sensitive medical information. The coordination process is designed to maintain compliance with both Swiss data protection requirements and, where applicable, the data protection obligations of the patient's home jurisdiction.
The international second opinion represents an established component of evidence-based medical practice, particularly relevant for complex neurological conditions requiring advanced diagnostics, neurosurgical intervention, or comprehensive neurorehabilitation. The value of independent expert review is well-documented in medical literature, with studies demonstrating that second opinions result in meaningful changes to diagnosis or treatment recommendations in a significant proportion of cases. For international patients, accessing a second opinion within a different institutional and healthcare system provides an additional dimension of independence and objectivity.
Neurological second opinions are particularly critical given the complexity of nervous system conditions and the irreversibility of many neurological deficits. Independent expert review may involve re-evaluation of neuroimaging with advanced post-processing techniques, re-interpretation of neurophysiological data, independent neuropathological review, and multidisciplinary neuroscience team assessment. For neurosurgical decisions — such as the extent of brain tumour resection, candidacy for epilepsy surgery, or appropriateness of deep brain stimulation — independent expert evaluation within a structured institutional framework can significantly influence the treatment trajectory and long-term neurological outcome.
The coordination of an international second opinion follows a structured pathway: secure compilation and transmission of existing medical records and diagnostic materials, institutional assignment based on the relevant subspecialty expertise, independent expert review by the receiving institution's clinical team, and transmission of a comprehensive written assessment with evidence-based recommendations. The timeline for a thorough second opinion evaluation typically ranges from one to four weeks depending on the complexity of the case and the need for additional diagnostic procedures. Throughout this process, the coordination function is strictly administrative — facilitating the organisational and logistical dimensions while respecting the absolute independence of the clinical evaluation and the patient's decision-making autonomy.
For complex neurological cases — including brain tumours in eloquent brain areas, treatment-refractory epilepsy, advanced movement disorders, complex cerebrovascular conditions, and rare neurological diseases — Switzerland offers advanced institutional capabilities. Access to ultra-high-field neuroimaging (7-Tesla MRI), stereotactic and functional neurosurgery, comprehensive epilepsy surgery programmes, established deep brain stimulation centres, and world-class neurorehabilitation facilities creates an institutional framework suited to the most challenging neurological presentations.
Beyond clinical capabilities, Switzerland offers several systemic attributes that are particularly relevant for complex international cases. System stability — Switzerland's political neutrality, economic stability, and mature institutional governance create an environment of predictability that is valued by patients navigating complex medical situations. Care predictability — the structured clinical pathway model, transparent cost framework, and established institutional protocols reduce uncertainty and facilitate planning. Coordination efficiency — compact geography, excellent transport infrastructure, and multilingual institutional capacity enable efficient movement between diagnostic, treatment, and rehabilitation phases. Rehabilitation infrastructure — Switzerland's globally recognised rehabilitation sector provides a natural continuum of care following acute treatment. Privacy framework — the combination of federal data protection legislation, medical professional secrecy, and institutional confidentiality culture provides a level of privacy protection that is among the strongest globally.
These attributes do not constitute a recommendation. The decision regarding where to seek medical evaluation or treatment is entirely personal and should be guided by the specific clinical situation, the relevant medical expertise available, and the patient's individual priorities and preferences. [Internal link: Why Switzerland Private Healthcare]
SwissAtlas operates as a neutral, non-medical institutional coordination platform. This positioning is fundamental to the integrity and value of the coordination service. SwissAtlas does not provide medical advice, clinical opinions, diagnostic assessments, or treatment recommendations under any circumstances. SwissAtlas does not evaluate, rank, endorse, or preferentially direct patients toward any specific medical institution, physician, or clinical programme.
The SwissAtlas coordination function encompasses exclusively non-clinical administrative and logistical services: the structuring and transmission of medical documentation, the identification of relevant institutional options based on the patient's stated requirements, the coordination of appointment scheduling and logistics, the management of accommodation, transport, and cultural support services, and the facilitation of communication between the patient's administrative contacts and institutional administrative personnel.
All clinical decisions — including the selection of a treating institution, the acceptance or rejection of proposed treatment plans, the pursuit or decline of second opinions, and all matters relating to medical care — are made exclusively by the patient in consultation with their chosen medical professionals. SwissAtlas's independence from any clinical role ensures that the coordination service operates without conflicts of interest and with complete alignment to the patient's autonomous decision-making.
This institutional positioning reflects SwissAtlas's commitment to operating within clearly defined boundaries that prioritise patient autonomy, institutional neutrality, and professional integrity. [Internal link: Private Coordination Services]
SwissAtlas is a non-medical coordination platform registered in Switzerland. SwissAtlas does not provide medical advice, clinical assessment, diagnostic services, treatment recommendations, or any form of healthcare service. All information presented on this page and throughout the SwissAtlas platform is provided for general educational and informational purposes only and does not constitute medical advice or a substitute for professional medical consultation.
SwissAtlas does not evaluate, rank, endorse, recommend, or express any preference regarding any medical institution, healthcare provider, clinical programme, or treatment modality. The coordination services provided by SwissAtlas are exclusively non-clinical and administrative in nature, encompassing logistical facilitation, documentation coordination, and communication support.
All medical decisions, including the selection of healthcare institutions, the acceptance or refusal of proposed diagnostic or treatment plans, and all matters relating to individual healthcare, are the sole responsibility of the patient and their chosen medical professionals. Patients are strongly encouraged to seek independent medical advice from qualified healthcare professionals before making any healthcare decisions.
The information provided on this page may not reflect the most current medical research, clinical guidelines, or institutional capabilities. Medical knowledge evolves continuously, and patients should rely on their treating physicians for current, individualised medical guidance.
The SwissAtlas coordination process for neurology follows a structured, four-phase framework designed to ensure administrative clarity, institutional alignment, and logistical precision at every stage. This process operates independently of all clinical decision-making, which remains exclusively within the domain of the patient and their chosen medical professionals.
The coordination process begins with a confidential written exchange, during which the patient or their representative provides a general description of the medical situation and coordination requirements. All communications are handled under strict confidentiality protocols consistent with Swiss data protection legislation. At this stage, SwissAtlas conducts a non-medical administrative assessment to understand the coordination needs, logistical requirements, and institutional preferences. No medical assessment, clinical opinion, or treatment recommendation is provided. The focus is exclusively on understanding the administrative and logistical dimensions of the coordination request.
Based on the general nature of the clinical situation and the patient's expressed requirements — including language preferences, privacy considerations, geographical preferences within Switzerland, treatment complexity, and logistical factors — appropriate Swiss institutions with relevant neurology capabilities are identified from SwissAtlas's curated network. This process is informational and facilitative only; no clinical recommendation or institutional ranking is provided. The patient retains complete autonomy in institutional selection. SwissAtlas provides structured information about institutional capabilities, international patient experience, and coordination readiness, enabling the patient to make an informed decision.
Once the patient has selected an institution and the clinical team has confirmed the proposed evaluation or treatment pathway, SwissAtlas facilitates the direct engagement between the patient and the institution. This includes the secure transmission of medical documentation in structured format, coordination of initial consultation scheduling, and establishment of direct communication channels between the patient's administrative contacts and the institution's international patient office. All clinical discussions, diagnostic assessments, and treatment planning occur directly between the patient and the treating medical team. SwissAtlas's role is limited to administrative facilitation and communication support.
Throughout the active treatment phase and beyond, SwissAtlas coordinates the logistical dimensions of the patient journey. This includes appointment scheduling, accommodation arrangements near the treating institution, private transport coordination, visa documentation support where required, interpreter arrangements, cultural accommodation planning — including dietary requirements and prayer facilities — and ongoing communication facilitation. For cases requiring post-treatment rehabilitation, coordination extends to rehabilitation facility identification, transfer logistics, and continuity planning. The final phase addresses the patient's transition back to their home healthcare environment, including comprehensive medical summary transmission, follow-up schedule coordination, and establishment of ongoing communication channels for institutional follow-up as directed by the treating medical team.
SwissAtlas remains non-medical throughout all phases. All clinical decisions are made exclusively by the patient in consultation with their chosen medical professionals.
The duration of neurological treatment depends on the condition and treatment modality. Comprehensive diagnostic evaluation — including advanced neuroimaging (3-Tesla MRI, functional MRI, PET-CT), neurophysiological studies (EEG, EMG/NCS, evoked potentials), lumbar puncture analysis, and genetic testing — typically requires five to ten days. Neurosurgical procedures vary from one-day stereotactic interventions to complex craniotomies requiring seven to fourteen days of hospitalisation. Deep brain stimulation (DBS) surgery typically involves two hospital stays: one for electrode implantation (three to five days) and one for pulse generator placement and programming (two to three days). Rehabilitation following stroke or neurosurgery may require four to twelve weeks of inpatient neurorehabilitation. Ongoing neurological treatments — such as infusion therapies for multiple sclerosis or Parkinson's disease — may require periodic returns. SwissAtlas coordinates the complete timeline including rehabilitation and follow-up scheduling.
Hospital stays for neurosurgical procedures vary by complexity and approach. Stereotactic procedures — including Gamma Knife radiosurgery and stereotactic biopsy — are typically performed as day surgery or with one to two nights' hospitalisation. Endoscopic procedures for pituitary tumours or hydrocephalus typically require three to five days. Open craniotomy for brain tumour resection generally requires five to fourteen days depending on tumour location, complexity, and neurological function. Deep brain stimulation electrode placement requires three to five days. Complex procedures including cerebrovascular surgery (aneurysm clipping, AVM resection), skull base surgery, and awake craniotomy for tumours in eloquent brain areas may require seven to twenty-one days. Swiss neurosurgical centres follow structured post-operative protocols with intensive neurological monitoring, early mobilisation, and coordinated transition to neurorehabilitation when indicated.
Both Switzerland and Germany offer world-class neuroscience infrastructure. Swiss neurological institutions offer personalised care with lower patient-to-physician ratios and longer consultation times. Switzerland's data protection framework provides among the strongest privacy safeguards globally, which is particularly relevant for patients with neurological conditions that may carry social or professional sensitivity. Germany offers a larger number of certified neuroscience centres with higher patient volumes and generally lower treatment costs. Germany's epilepsy surgery programmes are among the world's most established. Both countries have access to the same diagnostic and therapeutic technologies. The choice should be guided by the specific neurological condition, institutional sub-specialty expertise, research and clinical trial access, and personal priorities including privacy, language support, and rehabilitation preferences.
Neurological treatment costs in Switzerland are generally 30–50% lower than equivalent treatment at major US academic medical centres. This differential applies to diagnostic evaluation, neurosurgical procedures, deep brain stimulation, and neurorehabilitation. Complex brain tumour surgery — combining microsurgery, intraoperative MRI, and neuromonitoring — is substantially less expensive in Switzerland than at leading US centres. Swiss institutions provide transparent pre-treatment cost estimates that facilitate planning. Ongoing treatment costs for chronic neurological conditions (medication, infusion therapy, monitoring) should also be considered in long-term planning. SwissAtlas provides general cost guidance; specific estimates come from the treating institution.
Recovery timelines vary dramatically depending on the neurological condition and treatment. Following stereotactic radiosurgery (Gamma Knife/CyberKnife), patients can typically travel within two to five days. After minimally invasive neurosurgery, one to three weeks before travel is recommended. After open craniotomy, three to six weeks is typical before long-distance travel. Stroke rehabilitation requires four to twelve weeks of intensive inpatient neurorehabilitation, with ongoing outpatient rehabilitation for months thereafter. Following deep brain stimulation surgery, initial programming and optimisation requires two to four weeks, with periodic follow-up for programming adjustments. Spinal cord injury rehabilitation is among the most intensive and prolonged, potentially requiring three to six months of inpatient rehabilitation. Swiss neurorehabilitation programmes are among the world's most comprehensive and can significantly influence long-term functional outcomes.
Neurological second opinions are well-established in Swiss practice and are particularly valuable for complex diagnostic situations (atypical presentations, inconclusive investigations), surgical decision-making (brain tumour resection extent, epilepsy surgery candidacy), chronic neurological conditions (multiple sclerosis treatment escalation, movement disorder management), and rare neurological diseases. Swiss neurological institutions offer comprehensive second opinion services involving review of existing neuroimaging, neurophysiology studies, laboratory results, pathology specimens, and clinical records. The review is conducted by subspecialist neurologists and, where relevant, neurosurgeons with expertise in the specific condition. Advanced imaging may be repeated using Swiss institutional protocols for comparison. The process takes one to three weeks and provides a detailed assessment with evidence-based recommendations.
For urgent neurological situations — such as progressive neurological deficit, suspected CNS infection, or acute stroke (within the hyperacute treatment window) — Swiss institutions have established emergency pathways. For planned evaluation and treatment, diagnostic workup can typically begin within one to two weeks of receiving medical records. Neurosurgical procedures can be scheduled within two to six weeks depending on complexity and institutional scheduling. Deep brain stimulation involves a staged process over four to eight weeks. Gamma Knife/CyberKnife treatments can often be arranged within two to three weeks. SwissAtlas coordinates the administrative pathway to minimise delays.
Swiss neurological institutions treat the complete spectrum of neurological disorders including brain tumours (gliomas, meningiomas, metastases, acoustic neuromas, pituitary tumours), cerebrovascular disease (stroke, aneurysms, arteriovenous malformations, cavernomas), epilepsy (medical management, presurgical evaluation, epilepsy surgery, vagus nerve stimulation), movement disorders (Parkinson's disease, essential tremor, dystonia — including deep brain stimulation), multiple sclerosis and neuroimmunological disorders, neuromuscular diseases (ALS, myasthenia gravis, muscular dystrophies, neuropathies), headache disorders (migraine, cluster headache), dementia and cognitive disorders (Alzheimer's disease, frontotemporal dementia), spinal cord conditions, sleep disorders, and rare neurological diseases. Paediatric neurology and neurosurgery are also available at specialised Swiss centres.
Deep brain stimulation (DBS) is available at several Swiss neuroscience centres with established expertise. DBS involves the surgical implantation of electrodes into specific brain targets and a pulse generator (neurostimulator) that delivers controlled electrical stimulation. Established indications include Parkinson's disease (subthalamic nucleus or globus pallidus stimulation), essential tremor (ventral intermediate nucleus stimulation), dystonia (globus pallidus stimulation), and obsessive-compulsive disorder (treatment-resistant). Swiss DBS programmes offer comprehensive pre-surgical evaluation, intraoperative microelectrode recording for precise targeting, and long-term programming and follow-up. Advanced DBS technologies — including directional leads, sensing-enabled stimulators, and adaptive (closed-loop) stimulation — are available at leading Swiss centres.
Swiss neurological institutions offer the full range of advanced neuroimaging modalities including 3-Tesla and 7-Tesla MRI (structural, functional MRI, diffusion tensor imaging, MR spectroscopy, perfusion imaging), PET-CT with specialised tracers (FDG, amyloid, tau, DOPA), CT angiography and perfusion, digital subtraction angiography (DSA), SPECT imaging, and advanced post-processing with AI-assisted analysis. These imaging capabilities are essential for precise diagnosis, treatment planning, and monitoring across the full spectrum of neurological conditions. Intraoperative MRI and neuronavigation systems enhance surgical precision for brain tumour surgery and functional neurosurgery.
Epilepsy surgery is available at Swiss centres with established comprehensive epilepsy programmes. The presurgical evaluation process is rigorous and typically includes prolonged video-EEG monitoring (to characterise seizure semiology and EEG patterns), high-resolution 3-Tesla MRI (with epilepsy-specific protocols), PET imaging, neuropsychological testing, and where indicated, invasive EEG monitoring with intracranial electrodes (stereo-EEG). Surgical options include temporal lobectomy (the most common and well-established epilepsy surgery), lesionectomy, cortical resection, and disconnection procedures. Stereotactic laser ablation (LITT) and responsive neurostimulation represent newer approaches. Swiss epilepsy centres follow established international protocols and report outcomes consistent with leading global centres.
Switzerland offers world-class neurorehabilitation facilities with comprehensive programmes for stroke recovery, traumatic brain injury, spinal cord injury, post-neurosurgical rehabilitation, and neurological disease management. Swiss neurorehabilitation programmes are distinguished by high therapist-to-patient ratios, access to advanced rehabilitation technologies (robotic-assisted gait training, virtual reality, transcranial magnetic stimulation, computer-assisted cognitive rehabilitation), interdisciplinary teams (neurologists, physiatrists, physiotherapists, occupational therapists, speech-language pathologists, neuropsychologists, social workers), and individualised goal-oriented programmes. Facilities range from acute rehabilitation units within university hospitals to dedicated rehabilitation clinics in therapeutic settings. Early initiation of neurorehabilitation — during the acute hospital stay — is a key principle of Swiss neurological care.
Learn more about private coordination or how international patients access Swiss healthcare.
All medical decisions are made exclusively by the patient and their treating physicians.
Related pages: Healthcare Coordination · International Patients · GCC Families · Why Switzerland · Switzerland vs US · Clinics · Private Coordination
If you are managing a situation that requires immediate discretion and institutional-level coordination in Switzerland, we are available to respond within a few hours.
All enquiries are handled confidentially and without obligation.
Contact: contact@swissatlas.ch